Citatuzumab bogatox

Drug Profile

Citatuzumab bogatox

Alternative Names: VB6-845; VB6-845d

Latest Information Update: 27 Sep 2016

Price : $50

At a glance

  • Originator Viventia Biotech
  • Developer Eleven Biotherapeutics
  • Class Antineoplastics; Recombinant fusion proteins
  • Mechanism of Action Protein synthesis inhibitors; Ribosomal protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 21 Sep 2016 Viventia Biotechnologies has been acquired by Eleven Biotherapeutics
  • 18 Apr 2016 This programme is still active
  • 19 Jan 2016 Viventia Bio extends patent protection of pending applications to at least 2036 for VB 6845d (Viventia Bio Inc Pipeline, January 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top